AGN News Alert Allergan Inc (AGN) 205.75 12/16/2014 21:50:31

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Allergan Inc (AGN) 205.75 $AGN

Great Stocks: Valeant Pharmaceuticals Near Buy Point
at Investor's Business Daily - Tue Dec 16, 5:11PM CST
Drugmaker Valeant Pharmaceuticals is working on a new base as it prepares to issue its 2015 financial outlook. The base's cup-with-handle pattern shows a potential buy point at 147.49. But it's a risky, late-stage pattern, forming after the stock had...
AGN: 205.75 (-3.26), ACT: 256.52 (-6.48), VRX: 136.92 (-1.24)

Allergan Set to Possibly Rebound After Yesterday's Selloff of 1.29%
Comtex SmarTrend(R) - Tue Dec 16, 4:06PM CST
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $206.08 to a high of $209.00. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $208.47 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 205.75 (-3.26)

Allergan (AGN) Approaches New Downside Target of $207.30
Comtex SmarTrend(R) - Tue Dec 16, 11:40AM CST
Allergan (AMEX:AGN) has opened bearishly below the pivot of $209.57 today and has reached the first level of support at $208.16. Investors may be interested in a cross of the next downside pivot targets of $207.30 and $205.03.
AGN: 205.75 (-3.26)

Actavis unveils post-Allergan management structure
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 8:33AM CST

AGN: 205.75 (-3.26), ACT: 256.52 (-6.48)

Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Allergan Acquisition
PR Newswire - Tue Dec 16, 6:30AM CST
Actavis plc (NYSE: ACT) today announced the planned senior management team that will lead the global pharmaceutical company following the successful close of the acquisition of Allergan, Inc., anticipated in the second quarter of 2015. Brent Saunders will continue to lead Actavis as CEO and President and a member of the Board of Directors. Paul Bisaro will remain Executive Chairman of the Board of Directors. Mr. Saunders will lead an expanded senior management team comprised of leaders from both Actavis and Allergan, designed to further enhance the Company's position as the fastest growing and most dynamic growth pharmaceutical company in global healthcare.
AGN: 205.75 (-3.26), ACT: 256.52 (-6.48)

New Research from Allergan Reveals that the Quest to Look Younger is No Longer a Beauty Priority for Women
PR Newswire Europe - Tue Dec 16, 1:31AM CST
MARLOW, England, December 16, 2014 /PRNewswire/ --
AGN: 205.75 (-3.26)

Buffett and Billionaire Investors Look to Oil, Health Care and Spinoffs in 2015
at The Street - Mon Dec 15, 8:27AM CST
With 2014 nearly over, the question now becomes which stocks, sectors and strategies billionaire investors will be betting on in 2015. A few predictions.
VIPS: 19.83 (-0.67), ACT: 256.52 (-6.48), F: 14.09 (-0.19), TLM: 7.58 (+2.46), AXP: 88.24 (-1.80), ATLS: 25.41 (-0.33), AET: 85.64 (-1.03), ENR: 127.00 (+1.23), ZTS: 40.85 (-0.89), AGN: 205.75 (-3.26), V: 253.41 (-3.29), GMO: 0.34 (+0.04), RIG: 16.78 (+0.53), EBAY: 55.94 (+0.50), THC: 48.36 (-0.90), BAX: 70.73 (-0.37), CHK: 17.45 (+0.23), AAL: 47.96 (-2.88), GM: 30.73 (-0.27), IDIX: 24.50 (+0.05), MA: 82.64 (-1.97)

Top Healthcare Stocks for 2014
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 14, 10:03AM CST
Source: Flickr user  Tax Credits . This past year has been a great one for healthcare investors -- the S&P healthcare index ETF offered double the return of the S&P 500. Biotechnology stocks dominated the list of the 10 top-performing...
MNK: 91.05 (-1.12), MDVN: 102.50 (-1.58), CNC: 101.19 (-1.75), AGN: 205.75 (-3.26), VRTX: 110.86 (-2.02), ALNY: 92.08 (-1.87), EW: 125.44 (-1.57), ILMN: 175.18 (-3.13), SNY: 45.38 (+0.98), REGN: 396.13 (-4.88), PBYI: 195.44 (+0.11)

Uptrend Call Working As Allergan Stock Rises 24.8% (AGN)
Comtex SmarTrend(R) - Fri Dec 12, 4:49PM CST
SmarTrend identified an Uptrend for Allergan (AMEX:AGN) on September 11th, 2014 at $167.11. In approximately 3 months, Allergan has returned 24.75% as of today's recent price of $208.47.
AGN: 205.75 (-3.26)

After Yesterday's Decline of 1.26%, Allergan Offers Investors Better Value
Comtex SmarTrend(R) - Fri Dec 12, 4:03PM CST
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $208.47 to a high of $210.59. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $209.85 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
AGN: 205.75 (-3.26)

Cerebral Palsy - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/zdwf83/cerebral_palsy) has announced the addition of the "Cerebral Palsy - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cerebral Palsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cerebral Palsy and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cerebral Palsy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cerebral Palsy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Allergan - Acorda Therapeutics, Inc. - Neuralstem, Inc. - CHA Bio & Diostech Co., Ltd. - K-Stemcell Co., Ltd. - Cell Cure Neurosciences, Ltd. - Cellular Biomedicine Group, Inc. For more information visit http://www.researchandmarkets.com/research/zd...bral_palsy
AGN: 205.75 (-3.26), ACOR: 38.25 (-0.15), CBMG: 12.84 (-0.75), CUR: 2.37 (-0.02)

Merck Reveals Data from Breast Cancer Study on Keytruda - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 4:10PM CST
Merck (MRK) announced early data from the phase Ib study on its anti-PD-1 therapy, Keytruda.
AGN: 205.75 (-3.26), MRK: 56.80 (-0.15), BMY: 57.69 (-0.86)

Wilshire Confirms First-to-File Patent Challenge Relating to LASTACAFT®
PR Newswire - Thu Dec 11, 2:18PM CST
Wilshire Pharmaceuticals, Inc. ("Wilshire" today confirmed that it has been sued by Allergan, Inc. and Vistakon Pharmaceuticals, LLC (collectively, "Allergan" in connection with Wilshire's filing of an Abbreviated New Drug Application ("ANDA" with the U.S. Food and Drug Administration ("FDA" for Alcaftadine (alcaftadine ophthalmic solution) 0.25%. This product is the generic version of LASTACAFT® (alcaftadine ophthalmic solution) 0.25%, which is indicated for the prevention of itching associated with allergic conjunctivitis.
AGN: 205.75 (-3.26)

Roche (RHHBY) Presents Positive Data on Haemophilia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 4:16PM CST
Roche (RHHBY) announced data on its pipeline candidate ACE910 at the 56th American Society of Hematology.
AGN: 205.75 (-3.26), ABBV: 65.25 (-0.37), BIOD: 1.30 (-0.02)

Allergan Leads The 20 Best Value Bond Trades With A Maturity Of 1 Year Or More
Donald van Deventer - at Seeking Alpha - Wed Dec 10, 11:17AM CST

BDX: 134.04 (-1.71), BCR: 165.84 (-0.37), AXP: 88.24 (-1.80), TMO: 121.55 (-2.18), WBK: 25.91 (+0.05), AMT: 95.78 (-1.67), C: 51.17 (-1.62), AMGN: 159.44 (-0.16), CELG: 110.09 (-1.79), MCO: 92.38 (-1.41), AGN: 205.75 (-3.26), T: 32.14 (-0.11), GS: 183.31 (-2.23), JPM: 58.43 (-0.73), GILD: 100.46 (-2.70), MMP: 75.80 (-0.77)

The Zacks Analyst Blog Highlights: Novartis, Amgen, Incyte and Allergan
PR Newswire - Wed Dec 10, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Novartis (NYSE:NVS-Free Report), Amgen (Nasdaq:AMGN-Free Report), Incyte Corp. (Nasdaq:INCY-Free Report) and Allergan (NYSE:AGN-Free Report).
AGN: 205.75 (-3.26), INCY: 71.62 (-0.52), AMGN: 159.44 (-0.16), NVS: 91.65 (+0.01)

Herb Greenberg: What's Next for Valeant After Its Botched Bid for Allergan
at The Street - Wed Dec 10, 8:18AM CST
Has the pharmaceutical company really changed its strategy?
AGN: 205.75 (-3.26), VRX: 136.92 (-1.24)

Jim Cramer on the Stock Market: Activists Give Up on the Losers
at The Street - Wed Dec 10, 7:48AM CST
And that's too bad, because United Tech and McDonald's are begging for turnarounds.
AGN: 205.75 (-3.26), GE: 24.49 (-0.10), UTX: 113.23 (+1.32), MCD: 88.72 (+0.26), DOW: 42.71 (-0.74), WEN: 8.51 (-0.11), PEP: 92.59 (-1.55), BKW: 35.50 (-1.16)

Jim Cramer's 'Mad Money' Recap: Why Tuesday's Market Decline Made Sense
at The Street - Tue Dec 09, 7:32PM CST
The international markets pulled U.S. stocks lower but they were able to bounce back despite bad news from Verizon, Bank of America and Citi.
EA: 45.45 (unch), HON: 96.38 (+0.57), UTX: 113.23 (+1.32), C: 51.17 (-1.62), SNE: 19.72 (unch), BBY: 35.77 (-1.14), PEP: 92.59 (-1.55), AGN: 205.75 (-3.26), ATVI: 19.38 (-0.64), ETP: 61.46 (+2.14), SAVE: 68.70 (+0.11), TRGP: 91.28 (+0.42), WMB: 41.84 (-0.30), TEX: 25.66 (-0.45), AYR: 19.71 (-0.12), CAT: 89.34 (-0.41), MSFT: 45.16 (-1.51), UNP: 112.20 (-0.14), GME: 31.92 (-1.01), PDS: 5.57 (+0.22), BAC: 16.72 (-0.13), BKW: 35.50 (-1.16), MHR: 3.12 (+0.28), CONN: 14.15 (-1.63), MRK: 56.80 (-0.15), FLS: 54.90 (+0.10), MCD: 88.72 (+0.26), BRK.B: 145.28 (-0.84), VZ: 45.53 (+0.11), AMFW: 12.71 (+0.46), NRG: 25.83 (-0.29), WEN: 8.51 (-0.11)

Novartis Reports Encouraging Data on Biosimilar of Neupogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 2:15PM CST
Novartis (NVS) announced that its generic arm, Sandoz, reported encouraging data from a phase III study, PIONEER.
AGN: 205.75 (-3.26), INCY: 71.62 (-0.52), AMGN: 159.44 (-0.16), NVS: 91.65 (+0.01)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trilith Holiday Tour Blends Film Access and Giving

Updated Category News Views 53

Snow machines, trolley rides, and a mental-health subsidy are sharing the same stage in Fayetteville this holiday season. That is an unusual mix, but it fits Trilith Foundation’s stated mission better than another generic lights-and-cocoa event ever could. From Nov. 21 through Dec. 31, the Foundation is turning its guided Trilith Studios tour into a seasonal experience...

Continue Reading
LASIK Cost Math Deserves a Careful Second Look Today

Updated Category News Views 66

Thirty years of lens purchases can become a nasty tab Contact-lens spending has a funny way of staying invisible until somebody stacks the receipts into one ugly pile. A new cost-of-vision analysis from the surgeon advisory board of BestLASIKSurgeons.com says the average American contact-lens wearer may spend between $22,500 and $30,000 on corrective eyewear across 30...

Continue Reading
Stand Takes Colorado Bet on Wildfire-Smart Coverage

Updated Category News Views 90

Colorado’s insurance mess has finally attracted a company willing to price the driveway, the vents, and the tree line instead of shrugging at an entire ZIP code. Stand has launched homeowners coverage across the state, including mountain communities where wildfire exposure has made insurance both costly and scarce. This is not a small problem dressed up with a shiny...

Continue Reading
Medical School Rejections Carry a Steep Price Tag Too

Updated Category News Views 81

A rejection letter can turn into a remarkably expensive piece of paper. BeMo Academic Consulting's new Medical School Admissions Trends Report argues that the damage from missing medical-school admission goes far beyond bruised confidence: applicants can spend thousands chasing another cycle, lose time entering practice, and, if they never get in, forgo what the report...

Continue Reading
AI Echo Study Sharpens a Difficult HFpEF Diagnosis

Updated Category News Views 71

A single echo clip may be doing more useful work than plenty of flashy healthcare AI demos. The November 2026 Journal of Cardiac Failure focus issue puts a hard number on that possibility: pairing an AI read of a routine echocardiogram clip with the H?FPEF clinical score identified 78% of patients with hemodynamically confirmed HFpEF, versus 48% with the score alone. That...

Continue Reading
Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 124

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading
AMPERA Joins Berto to Power Future Energy Innovations

Updated Category News Views 58

The Power Play You Didn't See Coming AMPERA and Berto just made a move that could stir up some serious waves in the energy sector. They've inked a business combination deal set to push advanced energy technology to the forefront. With AMPERA's valuation clocking in at roughly $900 million, this partnership aims to bring cutting-edge power solutions from concept to market....

Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector

Updated Category News Views 67

Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 20

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 146

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading

Top 5 Most Recently Viewed Articles

Estimating the Growth of $100 in Webster Financial Shares

Updated Category News Views 237

Understanding Webster Financial's Long-Term Growth Webster Financial, trading under the symbol WBS, has demonstrated a remarkable performance in the stock market over the past five years. The investment landscape can be unpredictable, but looking at WBS, we can observe that it has outperformed the market by an average of 3.91% annually, yielding a total annual return of...

Continue Reading
Grocery Outlet Shareholders Can Pursue Securities Fraud Claims

Updated Category News Views 129

Grocery Outlet Shareholders Can Pursue Securities Fraud Claims Investors have the chance to reclaim their losses after allegations of securities fraud at Grocery Outlet Holding Corp. (NASDAQ: GO). It’s crucial for all purchasers of Grocery Outlet securities who were active during the defined Class Period to understand their rights. Understanding the Class Period The...

Continue Reading
Core Bank Expands Services with New Banking Center Soon

Updated Category News Views 135

Core Bank Relocation to a New Overland Park Facility Core Bank is thrilled to announce its move to a new location for its Overland Park Banking Center. This relocation marks a significant milestone for the bank, allowing it to better serve the growing needs of the community. The modern banking space, set to open soon, is designed with improved accessibility and enhanced...

Continue Reading
Exploring Netflix's Recent Options Activity and Insights

Updated Category News Views 189

Netflix's Recent Options Trading Trends Financial giants have expressed a notable bullish sentiment toward Netflix. Analyzing the recent options trades for Netflix (NASDAQ: NFLX) reveals that 65 unusual trades have taken place, sparking considerable interest among investors. Traders' Sentiments and Volume Analysis Diving into the details, about 56% of traders exhibited...

Continue Reading
Simply Good Foods Faces Securities Fraud Lawsuit Turmoil

Updated Category News Views 53

Simply Good Foods: Murky Waters  Well, here we go again with yet another corporate mess. Simply Good Foods Company’s staring down a securities class action lawsuit over not-so-savory business moves that have knocked their stock into the gutter. The beef? Failing to spill the beans on troubles brewing from an acquisition that's gone south. Now, they’re facing a...

Continue Reading